An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board

